675 reports of this reaction
1.4% of all LINACLOTIDE reports
#14 most reported adverse reaction
FLATULENCE is the #14 most commonly reported adverse reaction for LINACLOTIDE, manufactured by Allergan, Inc.. There are 675 FDA adverse event reports linking LINACLOTIDE to FLATULENCE. This represents approximately 1.4% of all 49,123 adverse event reports for this drug.
Patients taking LINACLOTIDE who experience flatulence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FLATULENCE is a less commonly reported adverse event for LINACLOTIDE, but still significant enough to appear in the safety profile.
In addition to flatulence, the following adverse reactions have been reported for LINACLOTIDE:
The following drugs have also been linked to flatulence in FDA adverse event reports:
FLATULENCE has been reported as an adverse event in 675 FDA reports for LINACLOTIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FLATULENCE accounts for approximately 1.4% of all adverse event reports for LINACLOTIDE, making it a notable side effect.
If you experience flatulence while taking LINACLOTIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.